Illumina Europe, Middle East, Africa and Latin America — Total Revenue increased by 7.2% to $356.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.2%, from $332.00M to $356.00M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing adoption of genomic sequencing tools and expanding market share in these regions, while a decrease may signal regional economic headwinds or increased local competition.
This metric represents the total net revenue generated from the sale of sequencing instruments, consumables, and related...
Comparable to regional revenue reporting for other global life science and medical device companies, though specific regional groupings vary by firm.
ilmn_segment_europe_middle_east_africa_and_latin_america_total_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $320.00M | $313.00M | $351.00M | $316.00M | $308.00M | $290.00M | $301.00M | $332.00M | $356.00M |
| QoQ Change | — | -2.2% | +12.1% | -10.0% | -2.5% | -5.8% | +3.8% | +10.3% | +7.2% |
| YoY Change | — | — | — | — | -3.8% | -7.3% | -14.2% | — | +7.2% |